Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study

In a multicentre prospective study of patients with renal cell carcinoma treated with nivolumab after the failure of antiangiogenic agents, nivolumab was associated with shorter progression-free survival (2.8 vs 4.6 months; p = 0.0045) and lower objective response rate (14.8% vs 23.3%) in patients with bone metastases at inclusion compared to patients without bone metastases. A post-hoc analysis of patients who received bone-modifying agents--either denosumab or bisphosphonates--at baseline (25%) found significant benefit of bone-modifying agents on the incidence of skeletal-related events (odds ratio, 0.367; 95% CI: 0.151-0.895).